Prevalence Of Irritable Bowel Syndrome In Patients Research Articles

Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis

ObjectiveTo evaluate the prevalence of symptoms and factors associated with irritable bowel syndrome (IBS) in axial spondyloarthritis (ax-SpA).MethodsIn a cross-sectional multicentric study, consecutive patients with ax-SpA treated with biologics in...

Prevalence of combination of functional dyspepsia and irritable bowel syndrome: a meta-analysis of studies using the Rome III-IV Criteria

To systematize data on the prevalence of the combination of functional dyspepsia (FD) and irritable bowel syndrome (IBS) using the Rome IIIIV Criteria. A search in electronic databases MEDLINE/PubMed, EMBASE, and Cochrane was conducted. The depth of search was 17 years (from January 2006 to May 2022). Original publications from peer-reviewed periodicals that applied the Rome IIIIV Criteria for diagnosis of FD and IBS in an adult patient population with detailed descriptive statistics to allow the resulting data to be included in the meta-analysis were selected for final analysis. The final analysis included 38 studies involving 17,993 patients with FD and 15,883 patients with IBS. In the overall pool of studies using the Rome IIIIV Criteria, the pooled prevalence of FD in patients with IBS was 34.625% (95% confidence interval [CI] 28.15941.390), and the pooled prevalence of IBS in patients with FD was 37.549% (95% [CI] 31.51143.787). A random-effects model was used in the analyses since significant heterogeneity between results was found (p0.0001; I298%). Using the Rome III Criteria, the pooled prevalence of FD in patients with IBS was 31.993% (95% CI 26.13538.150; I2=98.17%), while the prevalence of IBS in patients with FD was 34.694% (95% [CI] 29.31940.273; I2=97,89%). An analysis of papers using the Rome IV Criteria demonstrated that the pooled prevalence of FD in patients with IBS was 42.614% (95% CI 18.58868.675; I2=98.97%), and the prevalence of IBS in patients with FD was 50.444% (95% CI 37.95662.904; I2=94,39%). This meta-analysis demonstrated that the prevalence of the combination of FD and IBS identified using the Rome IIIIV Criteria is high and is reported in approximately 1 in 3 patients with the functional gastrointestinal disorders concerned. The prevalence of a combination of FD and IBS identified using the Rome IV Criteria is at least 10% higher than that using the Rome III Criteria.

Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis

Introduction. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) overlap is an adverse clinical situation, as patients with this syndrome have more severe clinical manifestations resulting in significant reductions in quality of life. For now, there are no meta-analytical papers that would summarize the frequency of FD – IBS overlap using the revised Rome IV criteria. Objective. To organize data on the prevalence of FD – IBS overlap using the revised Rome IV criteria.Materials and methods. A search for studies was conducted in MEDLINE / PubMed, EMBASE, Cochrane electronic databases. The search depth was 6 years (from January 2016 to February 2021). The final analysis included original publications from peerreviewed periodicals that used the revised Rome IV criteria as a method for diagnosing FD and IBS in the adult population with detailed descriptive statistics allowing to include resulting data in the meta-analysis.Results and discussion. The final analysis included 6 studies involving 1,180 patients with PD and 600 patients with IBS. The generalized prevalence of IBS in patients with PD was 41.511% (95% CI: 22.203–62.288). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 94.28%). The generalized prevalence of PD in patients with IBS was 38.791% (95% CI: 9.438–73.710). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 99.25%).Сonclusion. The complete meta-analysis showed that the frequency of FD - IBS overlap using the revised Rome IV criteria is quite high and accounts for about 40%. At the same time, further large studies of more homogeneous structure are needed to verify these results and study the potential pathogenetic relationship between PD and IBS.

ANKİLOZAN SPONDİLİT HASTALARINDA İRRİTABL BARSAK SENDROMU SIKLIĞI

OZ SUMMARY THE PREVALENCE OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH ANKYLOSING SPONDYLITIS Objective: Irritable bowel syndrome (IBS) is a functional bowel disease, characterized by altered bowel habits and chronic abdominal pain. IBS has an increased association with inflammatory pathologies such as rheumatoid arthritis (RA), but the role of inflammation in the pathophysiology of IBS hasn’t been clarified yet. Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton. The aim of our study is to determine the frequency of IBS in AS, and to reveal its relationship with other factors, primarily with disease activity. Material and Method: 145 patients with AS in the rheumatology clinic of Namik Kemal University were included. Along with demographic, clinical and laboratory data of the patients, disease activity and biologic drug use were recorded. The diagnosis and type of IBS were examined according to ROME III criteria. Results: The prevalence of IBS in patients with AS was 31.7%. Frequency of IBS was significantly higher in higher disease activity group (BASDAI>4) and in patients treated with biological agents (p values 4) ve biyolojik ajan tedavisi alanlarda anlamli sekilde yuksekti (p<0.001 ve p: 0.01 sirasiyla). Cinsiyetler arasinda IBS kadin hastalarda, yasa gore ise genc hastalarda (<50 yas) anlamli sekilde yuksekti (p: 0.012 ve p<0.01 sirasiyla). Sonuc: IBS; AS hastalarinda normal populasyona kiyasla daha yuksek (%31.7) tespit edildi. AS hastalik aktivite skoru ile IBS arasindaki iliski patogenezde inflamasyonun etkisini dusundurdu. Sonuc olarak ozellikle hastalik aktivitesi yuksek olan AS hastalarinda gastroenterolojik sikayetler sorgulanmali, sik bir komorbidite olan IBS takip surecinde goz ardi edilmemelidir.

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis.

Patients with microscopic colitis and patients with irritable bowel syndrome (IBS) present with similar symptoms. We examined the association between IBS and microscopic colitis in a systematic review and meta-analysis. We searched the medical literature to identify cross-sectional surveys or case-control studies reporting the association between microscopic colitis and IBS in 50 or more unselected adult patients. We recorded the prevalence of IBS symptoms in patients with histologically confirmed microscopic colitis, or the prevalence of histologically confirmed microscopic colitis in patients with IBS. Data were pooled using a random-effects model; the association between microscopic colitis and IBS was summarized using an odds ratio (OR) with a 95% confidence interval (CI). The search strategy identified 3926 citations, of which 10 were eligible for our analysis. The pooled prevalence of IBS in patients with microscopic colitis was 33.4% (95% CI, 31.5%-40.6%), but was not significantly higher in patients with microscopic colitis than in patients with diarrhea (OR, 1.39; 95% CI, 0.43-4.47). In 3 cross-sectional surveys, the pooled OR for microscopic colitis in participants with IBS, compared with other patients with diarrhea, was 0.68 (95% CI, 0.44-1.04). In 4 case-control studies the prevalence of IBS in patients with microscopic colitis was significantly higher than in asymptomatic controls (OR, 5.16; 95% CI, 1.32-20.2). Based on a meta-analysis, one third of patients with microscopic colitis reported symptoms compatible with IBS, but the prevalence of IBS was no higher than in other patients with diarrhea. The odds of microscopic colitis were no higher in patients with IBS compared with other patients with diarrhea. The value of routine colonoscopy and biopsy to exclude microscopic colitis in patients with typical IBS symptoms, unless other risk factors or alarm symptoms are present, remains uncertain.

Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes

The irritable bowel syndrome (IBS) is the best known of the functional gastrointestinal tract disorders. Many IBS patients have at least one co-morbid somatic complaint and many meet diagnostic criteria for other functional disorders. Patients with IBS and another functional disorder, in comparison with patients with IBS only, have more severe IBS symptoms, a higher rate of psychopathology, greater impairment of quality of life, and more illness-related work absenteeism. Estimates of the prevalence of IBS in patients with fibromyalgia range from 30-35% to as high as 70%. Studies of IBS among patients with chronic fatigue syndrome have reported a prevalence ranging from 35-92%. The prevalence of IBS among patients with chronic fatigue syndrome is reported to be 14%. IBS patients with other co-morbid functional disorders appear to manifest a greater degree of somatization. It has been suggested that the presence of multiple co-morbid disorders may be a marker for psychological influences on etiology. This raises the question of whether the functional syndromes represent the same pathophysiological process, i.e., are the same entity that has been separated into different clinical entities because of medical sub-specialization, or are indeed separate disorders. While the answer to this question awaits further research, it would appear that most functional patients who meet formal diagnostic criteria for more than one functional disorder manifest one disorder clinically more that the others and seek consultation differentially for that set of symptoms.

Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature

Evidence points to a significant overlap between irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). In this study, we evaluate this overlap by conducting a systematic review of the literature. Six electronic databases from 1966 through January 2005 were screened by multiple search terms to identify all epidmiological evidence linking IBS and GERD. In addition, AGA meeting abstracts for 2003 and 2004 were also screened. All studies were validated by the authors and data extracted according to predefined criteria. As a separate search strategy, studies evaluating the prevalence of IBS and GERD in the general population were sought. These articles were obtained to compare the prevalence of IBS and GERD in the community to the degree of overlap. The search identified 997 original titles with 15 publications that fulfilled our eligibility criteria. Among the 15 studies, 7 determined the GERD maximum mean prevalence in patients already diagnosed with IBS to be 39.3% and the weighted mean 30.3%. The other 7 studies examined the prevalence of IBS in patients already diagnosed with GERD. The maximum mean prevalence of IBS in subjects with known GERD was 48.8% and the weighted mean 60.5%. Based on the prevalence of IBS (12.1%) and GERD (19.4%) in the community, the rate of IBS in the non-GERD community was calculated to be only 5.1%. There is a strong overlap between GERD and IBS that exceeds the individual presence of each condition. In the absence of GERD, IBS is relatively uncommon.

The relationship between schizophrenia and irritable bowel syndrome (IBS)

Irritable bowel syndrome (IBS) has been reported in 10–22% of adults. Amongst patients seeking medical attention for IBS 70–90% may have psychiatric co-morbidity, most commonly major depression. In contrast, few studies have looked at the prevalence of IBS in psychiatric patients. To our knowledge, there are no studies assessing the prevalence of IBS in patients with schizophrenia. Using a semistructured clinical interview to study the prevalence of IBS, we compared 47 patients with schizophrenia to an age-matched control group ( n = 40) of patients who were seeking treatment in a primary care physicians office for other medical illnesses. IBS was diagnosed according to the criteria of Drossman et al. Nineteen percent ( n = 9) of the patients with schizophrenia met criteria for IBS in contrast to 2.5% ( n = 1) of the control group ( p = 0.012). Schizophrenic patients seldom complain of gastrointestinal symptoms until specifically asked. Therefore, it may be important to inquire about gastrointestinal symptoms prior to initiating pharmacotherapy in order to differentiate side effects from a prior existing condition. Prospective studies should address the question whether remission of psychosis leads to improvement or resolution of IBS.

Relationship between irritable bowel syndrome (IBS) and double depression (dysthymia plus major depression)

AbstractBackground: Irritable bowel syndrome (IBS) has been reported in a significant number of adults. To our knowledge, no study has looked at the prevalence of IBS in patients with double depression. Methods: Using a semi‐structured clinical interview to study the prevalence of IBS, we compared 26 patients seeking treatment for double depression (dysthymia plus major depression) to an age‐ and sex‐matched control group of patients (N = 40) who were seeking treatment in a general physician's office for other medical illnesses. The control group did not have any Axis I disorders. IBS was diagnosed according to the criteria of Dross man et al. (Gastroenterol Int 4:159–172, 1990). Results: 57.69% of patients with double depression met criteria for IBS in contrast with 2.5% of the control group (P = 0.0001). Patients with double depression were more likely to complain of symptoms of weakness, nocturnal bowel movements, and gastrointestinal symptoms related to stress as compared to patients in the control group. In 50% of patients, the psychiatric disease preceded the onset of the bowel disease, whereas in 37.5% of patients the bowel symptoms appeared first. Conclusions: IBS is common in patients with double depression. Clinicians should screen patients with psychiatric illness for IBS. Depression 3:303–308 (1995/1996). © 1996 Wiley‐Liss, Inc.